Anti-cytokeratin CAM5.2 (BD Biosciences) and CK8 give no remarkable advantages to the pancytokeratin cocktail of antibodies (AE1/AE3, CAM5.2, MNF116, CK8, and CK18) in detecting disseminated tumor cells in biologic subtypes of stage I-III breast cancer patients.
Wea-Lung
WL
Lin
Fong-Lin
FL
Chen
Chih-Ping
CP
Han
D001943:Breast Neoplasms / Q000145:classification* / Q000473:pathology*; D002280:Basal Cell Carcinoma / Q000556:secondary*; D005260:Female; D006801:Humans